Stockscreener 앱 받기
30.06
1.76%
-0.54
시간 외 거래:
29.77
-0.29
-0.96%
전일 마감가:
$30.60
열려 있는:
$30.42
하루 거래량:
1.38M
Relative Volume:
0.84
시가총액:
$18.52B
수익:
$2.62B
순이익/손실:
$966.70M
주가수익비율:
20.03
EPS:
1.5004
순현금흐름:
$1.09B
1주 성능:
-5.77%
1개월 성능:
-12.26%
6개월 성능:
+42.60%
1년 성능:
+59.13%
1일 변동 폭
$29.66
$30.42
1주일 범위
$29.66
$32.04
52주 변동 폭
$17.23
$35.43
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
30.06 | 18.85B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-04-01 | 다운그레이드 | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-04 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-08-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-15 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-12-06 | 업그레이드 | UBS | Neutral → Buy |
| 2023-11-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-11-08 | 업그레이드 | DNB Markets | Sell → Buy |
| 2023-10-18 | 개시 | Exane BNP Paribas | Underperform |
| 2023-09-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | 개시 | BTIG Research | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-31 | 개시 | UBS | Neutral |
| 2023-05-12 | 개시 | Morgan Stanley | Underweight |
| 2022-12-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-11-14 | 개시 | William Blair | Mkt Perform |
| 2022-11-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-06-24 | 개시 | BMO Capital Markets | Market Perform |
| 2022-05-02 | 개시 | Cowen | Market Perform |
| 2022-03-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-12-01 | 개시 | Berenberg | Sell |
| 2021-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | 개시 | Deutsche Bank | Buy |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | 다운그레이드 | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | 개시 | SVB Leerink | Mkt Perform |
| 2020-06-25 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | 개시 | Credit Suisse | Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-12 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-09-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | Morgan Stanley | Overweight |
| 2019-08-12 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Genmab Adr 주식(GMAB)의 최신 뉴스
Where is Genmab A/S (GMAB) Headed According to Wall Street? - Finviz
Oppenheimer Asset Management Inc. Acquires 61,311 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth - Chartmill
Targeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica - GlobeNewswire Inc.
Federated Hermes Inc. Makes New Investment in Genmab A/S Sponsored ADR $GMAB - MarketBeat
What is HC Wainwright’s Estimate for Genmab A/S Q4 Earnings? - Defense World
What is HC Wainwright's Estimate for Genmab A/S Q4 Earnings? - MarketBeat
HC Wainwright Boosts Earnings Estimates for Genmab A/S - MarketBeat
GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment - Chartmill
Stocks Showing Rising Market Leadership: BeOne Medicines ADR Earns 84 RS Rating - Investor's Business Daily
Genmab A/S (NASDAQ:GMAB) Shares Gap DownHere's What Happened - MarketBeat
GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation - Chartmill
GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals - Chartmill
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside - Finviz
Ascendis Pharma ADR shows rising price performance with jump to 83 RS rating - MSN
Genmab A/S (GMAB): A Bull Case Theory - Finviz
Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 - Investor's Business Daily
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Eagle Global Advisors LLC Buys 34,175 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab ADR Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Genmab A/S (NASDAQ:GMAB) Hits New 52-Week HighTime to Buy? - MarketBeat
Genmab A/S (OTCMKTS:GNMSF) Reaches New 1-Year HighShould You Buy? - MarketBeat
Moderna Stock Gets Healthy Relative Strength Rating Jump - Investor's Business Daily
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - MSN
Quoin Pharm ADR clears technical benchmark, hitting 90-plus RS rating - MSN
Genmab A/SAmerican Depositary Shares (NQ: GMAB - FinancialContent
Genmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week HighHere's What Happened - MarketBeat
Stocks To Watch: Immunocore Holdings ADR Sees RS Rating Rise To 83 - MSN
Genmab A/S (NASDAQ:GMAB) Shares Down 3.5% – Here’s Why - Defense World
Genmab A/S (NASDAQ:GMAB) Stock Price Down 3.5%Time to Sell? - MarketBeat
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus - TechStock²
Ascendis Pharma ADR reaches 80-plus relative strength rating benchmark - MSN
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Genmab Portfolio Prioritization Update - GlobeNewswire
Genmab–BioNTech cancer antibody trial ends early: What investors need to know - MSN
Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know - TipRanks
This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131% - Investor's Business Daily
Genmab A/S (NASDAQ:GMAB) Reaches New 1-Year HighStill a Buy? - MarketBeat
Squarepoint Ops LLC Has $1.95 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
China Universal Asset Management Co. Ltd. Has $381,000 Stake in Genmab A/S Sponsored ADR $GMAB - Defense World
The 5 Best Stocks To Buy And Watch Right Now - Investor's Business Daily
Pipeline of Proprietary Antibodies - flow – Deutsche Bank
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 86,842 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Bought by First Trust Advisors LP - Defense World
Quoin Pharm ADR Joins Rank Of Stocks With RS Ratings Over 90 - MSN
Dow Jones Stock Caterpillar In Buy Zone After Recent Breakout Move - Investor's Business Daily
Marshall Wace LLP Cuts Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Sold by American Century Companies Inc. - Defense World
Genmab Adr (GMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
2.01%
자본화:
|
볼륨(24시간):